[go: up one dir, main page]

ES2551281B1 - Topical cream product for the treatment of skin diseases and obtaining procedure - Google Patents

Topical cream product for the treatment of skin diseases and obtaining procedure Download PDF

Info

Publication number
ES2551281B1
ES2551281B1 ES201430703A ES201430703A ES2551281B1 ES 2551281 B1 ES2551281 B1 ES 2551281B1 ES 201430703 A ES201430703 A ES 201430703A ES 201430703 A ES201430703 A ES 201430703A ES 2551281 B1 ES2551281 B1 ES 2551281B1
Authority
ES
Spain
Prior art keywords
treatment
skin diseases
product
enoxolone
glycerin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201430703A
Other languages
Spanish (es)
Other versions
ES2551281A1 (en
Inventor
José RAMOS PRIETO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to ES201430703A priority Critical patent/ES2551281B1/en
Publication of ES2551281A1 publication Critical patent/ES2551281A1/en
Application granted granted Critical
Publication of ES2551281B1 publication Critical patent/ES2551281B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Producto en crema de uso tópico para el tratamiento de enfermedades de la piel y procedimiento de obtención, que comprende vaselina filante, ácido salicílico, aceite de mosqueta, vitamina A (retinol), enoxolona, agua destilada, glicerina y colorante, consistiendo el proceso de obtención en la mezcla de 92,699% de vaselina filante y 0,05% de enoxolona durante media hora; seguidamente, se añade 0,05% de vitamina A y se mezcla durante 10 minutos; luego se añade 0,15% de aceite de mosqueta y se mezcla durante 5 minutos; finalmente, se añaden 0,048% de agua destilada, 0,001% de colorante, 7,00% de ácido salicílico y 0,002% de glicerina, y se mezclan durante media hora. La mezcla obtenida se deja reposar durante cuatro horas en lugar refrigerado antes de envasar.Topical cream product for the treatment of skin diseases and procedure for obtaining, which comprises petrolatum, salicylic acid, nutmeg, vitamin A (retinol), enoxolone, distilled water, glycerin and dye, the process consisting of obtaining in the mixture 92.699% of petroleum jelly and 0.05% of enoxolone for half an hour; then, 0.05% of vitamin A is added and mixed for 10 minutes; then 0.15% nut oil is added and mixed for 5 minutes; finally, 0.048% distilled water, 0.001% dye, 7.00% salicylic acid and 0.002% glycerin are added, and mixed for half an hour. The mixture obtained is allowed to stand for four hours in a refrigerated place before packaging.

Description

DESCRIPCIÓN DESCRIPTION Producto en crema de uso tópico para el tratamiento de enfermedades de la piel y procedimiento de obtención. Topical cream product for the treatment of skin diseases and obtaining procedure.

5  5

OBJETO DE LA INVENCIÓN OBJECT OF THE INVENTION

La invención, tal como expresa el enunciado de la presente memoria descriptiva, se refiere a un producto en crema de uso tópico para el tratamiento de enfermedades de la piel y procedimiento de obtención. 10 The invention, as expressed in the present specification, refers to a topical cream product for the treatment of skin diseases and method of obtaining. 10

Más en particular, el objeto de la invención se centra en un producto especialmente indicado para el tratamiento de psoriasis, dermatitis, acnés, herpes, hongos u otras enfermedades de la piel mediante su uso en crema por aplicación directa sobre la zona afectada, siendo un segundo aspecto de la invención el procedimiento de obtención de dicho producto. 15 More particularly, the object of the invention focuses on a product especially indicated for the treatment of psoriasis, dermatitis, acnes, herpes, fungi or other skin diseases by using cream by direct application on the affected area, being a Second aspect of the invention is the process for obtaining said product. fifteen

CAMPO DE APLICACIÓN DE LA INVENCIÓN FIELD OF APPLICATION OF THE INVENTION

El campo de aplicación de la presente invención se enmarca dentro del sector de la industria dedicada a la fabricación de productos cosméticos y farmacéuticos, y más concretamente en 20 el campo de la elaboración de preparados para el tratamiento de enfermedades de la piel humana. The field of application of the present invention is part of the industry sector dedicated to the manufacture of cosmetic and pharmaceutical products, and more specifically in the field of the preparation of preparations for the treatment of human skin diseases.

ANTECEDENTES DE LA INVENCIÓN BACKGROUND OF THE INVENTION

25  25

Como referencia al estado actual de la técnica, cabe señalar que, si bien se conocen diferentes remedios para el tratamiento de las múltiples afecciones de la piel, al menos por parte del solicitante, se desconoce la existencia de ninguno que presente unas características técnicas, estructurales y constitutivas semejantes a las que en particular presenta el que aquí se preconiza, según se reivindica. 30 As a reference to the current state of the art, it should be noted that, although different remedies are known for the treatment of multiple skin conditions, at least by the applicant, the existence of none that has technical, structural characteristics is unknown. and constitutive ones similar to those in particular presented here, as claimed. 30

EXPLICACIÓN DE LA INVENCIÓN EXPLANATION OF THE INVENTION

La presente invención tiene, pues, como objetivo principal el desarrollo de un producto que, aplicado a las zonas afectadas por cualquiera de dichas enfermedades, permita una 35 curación de enfermedades de la piel como dermatitis, acnés, herpes, hongos, anteriormente citadas, incluida la psoriasis, después de un cierto período de tiempo de aplicación del mismo, así como la eliminación de los síntomas de picazón o escamado que generalmente llevan asociado dichas enfermedades, para lo cual dicho producto, configurado a modo de crema, es de uso tópico, siendo el procedimiento de preparación del mismo la realización de 40 una mezcla de los ingredientes que lo componen mediante una serie de combinaciones llevadas a cabo en un determinado orden y en una condiciones. The present invention therefore has as its main objective the development of a product that, applied to the areas affected by any of said diseases, allows a cure of skin diseases such as dermatitis, acnes, herpes, fungi, previously mentioned, including Psoriasis, after a certain period of application of the same, as well as the elimination of the symptoms of itching or scaling that are usually associated with these diseases, for which said product, configured as a cream, is topical, the preparation process thereof being the realization of a mixture of the ingredients that compose it by means of a series of combinations carried out in a certain order and under conditions.

En concreto, el producto preconizado, en una realización preferida, comprende los ingredientes que se describen a continuación en las proporciones indicadas: 45 In particular, the recommended product, in a preferred embodiment, comprises the ingredients described below in the indicated proportions:

- Vaselina filante ...................................................................92,699% - Filament Vaseline ............................................... .................... 92.699%

- Ácido salicílico ......................................................................7,00% - Salicylic acid ............................................... ....................... 7.00%

- Aceite de mosqueta ..............................................................0,15% - Mosqueta oil .............................................. ................ 0.15%

- Vitamina A (retinol) ...............................................................0,05% 50 - Vitamin A (retinol) ............................................ ................... 0.05% 50

- Enoxolona.............................................................................0,05% - Enoxolone ................................................ ............................. 0.05%

- Agua destilada .....................................................................0,048% - Distilled water ............................................... ...................... 0.048%

- Glicerina (E-422) ..................................................................0,002% - Glycerin (E-422) ........................................... ....................... 0.002%

- Colorante (violeta genciana cl4209) ..................................0,001% - Coloring (gentian violet cl4209) .................................. 0.001%

Por su parte, el producto de la composición anterior, se obtiene en base a un procedimiento que comprende las siguientes fases de elaboración: On the other hand, the product of the previous composition, is obtained based on a procedure that includes the following phases of elaboration:

5  5

- en primer lugar, se mezclan la vaselina filante y la enoxolona durante media hora; - firstly, the filament petrolatum and enoxolone are mixed for half an hour;

- seguidamente, se añade la vitamina A y se mezcla durante 10 minutos; - then, vitamin A is added and mixed for 10 minutes;

- luego se añade el aceite de mosqueta y se mezcla durante 5 minutos; 10 - then add the nutmeg oil and mix for 5 minutes; 10

- y finalmente, se añaden el resto de productos, es decir, el agua destilada, el colorante, el ácido salicílico y la glicerina, y se mezclan durante media hora; - and finally, the rest of the products are added, ie distilled water, dye, salicylic acid and glycerin, and mixed for half an hour;

- después, la mezcla se deja reposar durante cuatro horas en lugar refrigerado antes de 15 envasar. - Afterwards, the mixture is allowed to stand for four hours in a refrigerated place before packing.

Descrita suficientemente la naturaleza de la presente invención, así como la manera de ponerla en práctica, no se considera necesario hacer más extensa su explicación para que cualquier experto en la materia comprenda su alcance y las ventajas que de ella se derivan, 20 haciéndose constar que, dentro de su esencialidad, podrá ser llevada a la práctica en otras formas de realización que difieran en detalle de la indicada a título de ejemplo, y a las cuales alcanzará igualmente la protección que se recaba, siempre que no se altere, cambie o modifique su principio fundamental. Describing sufficiently the nature of the present invention, as well as the way of putting it into practice, it is not considered necessary to extend its explanation so that any expert in the field understands its scope and the advantages that derive from it, 20 stating that , within its essentiality, may be implemented in other embodiments that differ in detail from that indicated by way of example, and which will also achieve the protection sought, provided that it is not altered, changed or modified its fundamental principle.

Claims (4)

REIVINDICACIONES 1.- PRODUCTO EN CREMA DE USO TÓPICO PARA EL TRATAMIENTO DE ENFERMEDADES DE LA PIEL, caracterizado porque comprende los siguientes ingredientes: 5 1.- PRODUCT IN TOPICAL CREAM FOR THE TREATMENT OF SKIN DISEASES, characterized in that it comprises the following ingredients: - Vaselina filante - Filament Vaseline - Ácido salicílico - Salicylic acid - Aceite de mosqueta - Mosqueta oil - Vitamina A (retinol) 10 - Vitamin A (retinol) 10 - Enoxolona - Enoxolone - Agua destilada - Distilled water - Glicerina (E-422) - Glycerin (E-422) - Colorante - Colorant 15  fifteen 2.- PRODUCTO EN CREMA DE USO TÓPICO PARA EL TRATAMIENTO DE ENFERMEDADES DE LA PIEL, según la reivindicación 1, caracterizado porque los ingredientes que comprende se incorporan en las siguientes proporciones: 2. PRODUCT IN CREAM OF TOPICAL USE FOR THE TREATMENT OF SKIN DISEASES, according to claim 1, characterized in that the ingredients it comprises are incorporated in the following proportions: - Vaselina filante ...................................................................92,699% 20 - Filament Vaseline ............................................... .................... 92.699% 20 - Ácido salicílico ...................................................................7,00% - Salicylic acid ............................................... .................... 7.00% - Aceite de mosqueta ...........................................................0,15% - Mosqueta oil .............................................. ............. 0.15% - Vitamina A (retinol) ............................................................0,05% - Vitamin A (retinol) ............................................ ................ 0.05% - Enoxolona...........................................................................0,05% - Enoxolone ................................................ ........................... 0.05% - Agua destilada ...................................................................0,048% 25 - Distilled water ............................................... .................... 0.048% 25 - Glicerina (E-422) ................................................................0,002% - Glycerin (E-422) ........................................... ..................... 0.002% - Colorante.............................................................................0,001% - Colorant................................................ ............................. 0.001% 3.- PRODUCTO EN CREMA DE USO TÓPICO PARA EL TRATAMIENTO DE ENFERMEDADES DE LA PIEL, según la reivindicación 1 ó 2, caracterizado porque el 30 colorante es violeta genciana. 3. PRODUCT IN CREAM OF TOPICAL USE FOR THE TREATMENT OF SKIN DISEASES, according to claim 1 or 2, characterized in that the dye is gentian violet. 4.- PROCEDIMIENTO de obtención de un producto como el descrito en cualquiera de las reivindicaciones 1-3, caracterizado porque comprende las siguientes fases de elaboración: 4. PROCEDURE for obtaining a product as described in any of claims 1-3, characterized in that it comprises the following manufacturing phases: 35  35 - se mezcla la vaselina filante y la enoxolona durante media hora; - Blend Vaseline and enoxolone for half an hour; - seguidamente, se añade la vitamina A y se mezcla durante 10 minutos; - then, vitamin A is added and mixed for 10 minutes; - luego se añade el aceite de mosqueta y se mezcla durante 5 minutos; 40 - then add the nutmeg oil and mix for 5 minutes; 40 - y finalmente, se añaden el agua destilada, el colorante, el ácido salicílico y la glicerina, y se mezclan durante media hora; - and finally, distilled water, dye, salicylic acid and glycerin are added, and mixed for half an hour; - la mezcla obtenida se deja reposar durante cuatro horas en lugar refrigerado antes de 45 envasar. - the mixture obtained is allowed to stand for four hours in a refrigerated place before packaging.
ES201430703A 2014-05-14 2014-05-14 Topical cream product for the treatment of skin diseases and obtaining procedure Expired - Fee Related ES2551281B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201430703A ES2551281B1 (en) 2014-05-14 2014-05-14 Topical cream product for the treatment of skin diseases and obtaining procedure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201430703A ES2551281B1 (en) 2014-05-14 2014-05-14 Topical cream product for the treatment of skin diseases and obtaining procedure

Publications (2)

Publication Number Publication Date
ES2551281A1 ES2551281A1 (en) 2015-11-17
ES2551281B1 true ES2551281B1 (en) 2016-09-14

Family

ID=54478483

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201430703A Expired - Fee Related ES2551281B1 (en) 2014-05-14 2014-05-14 Topical cream product for the treatment of skin diseases and obtaining procedure

Country Status (1)

Country Link
ES (1) ES2551281B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593261B1 (en) * 2016-10-03 2017-07-10 Jose Ramos Prieto PRODUCT IN CREAM OF TOPICAL USE FOR THE TREATMENT OF SKIN DISEASES AND PROCEDURE OF OBTAINING

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2837704B1 (en) * 2002-04-02 2005-01-14 Oreal USE OF SAPOGENINE, OR NATURAL EXTRACT CONTAINING THEM, FOR THE TREATMENT OF OLIGOSEBORRHEIC DRY SKINS
JP2009046468A (en) * 2007-07-23 2009-03-05 Rohto Pharmaceut Co Ltd Skin care preparation for external use for wet skin
ES2315186B1 (en) * 2007-08-13 2010-01-08 Jose Ramos Prieto POMADA TO COMBAT AND TREAT SKIN DISEASES, AND PROCEDURE FOR PREPARATION OF SUCH POMADA.
GB0912481D0 (en) * 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
EP2387990A1 (en) * 2010-05-06 2011-11-23 Skinius S.R.L. Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies
BRPI1104422A2 (en) * 2011-09-05 2014-03-18 Riformula Farmacia De Manipulacao Ltda Me DERMATOLOGICAL COMPOSITION FOR TREATMENT OF TOPICAL USE PSORIASIS
CN102688168A (en) * 2012-06-06 2012-09-26 南通恒隆化工有限公司 Waterproof cold cream
BR102012022291B8 (en) * 2012-09-04 2022-03-15 Antonio Jose Trassi Product manufacturing process for the treatment of psoriasis
CN102908291A (en) * 2012-11-13 2013-02-06 沈阳信达信息科技有限公司 Hand cream containing angelica sinensis

Also Published As

Publication number Publication date
ES2551281A1 (en) 2015-11-17

Similar Documents

Publication Publication Date Title
CL2017001364A1 (en) New substituted indazoles, procedures for their preparation, pharmaceutical preparations containing them, as well as their use for the preparation of medicines.
MX2018012448A (en) Liposomal preparation and methods of treatment.
CL2017001614A1 (en) Process for increasing the stability of a composition comprising polyunsaturated omega-3 fatty acids
CL2017001613A1 (en) Process for increasing the stability of a composition comprising polyunsaturated omega-6 fatty acids
CL2017000475A1 (en) Compositions for cosmetic formulation comprising a mixture selected from murumuru butter, ucuuba butter, brazilian-nut oil, passion fruit oil, cupuassu butter, assai oil and/or nhandiroba oil and/or esters thereof, as well as the use of a mixture for the preparation of a cosmetic
CY1124710T1 (en) CETYLATED FATTY ACIDS, SYSTEM FOR THEIR PREPARATION AND USE THEREOF
DOP2016000076A (en) TIENOURACILCARBOXAMIDAS AND USES OF THE SAME
ES2551281B1 (en) Topical cream product for the treatment of skin diseases and obtaining procedure
GT201700126A (en) PIRIDIL-CICLOALQUIL-CARBOXYLIC ACIDS SUBSTITUTED COMPOSITIONS CONTAINING THEMSELVES AND USES OF THE SAME
AR108116A1 (en) DERMOCOSMETIC COMPOSITION, PROCESS OF PRODUCTION OF THE TOPICAL COMPOSITION, METHOD FOR STRENGTHENING OF FRAGILE NAILS AND USE OF COMPOSITION
CL2014002547A1 (en) Vesicular formulation in cream, lotion, ointment, gel, solution, spray, lacquer or filmogenic solution, comprising one or more phospholipids or sulpholipids and one or more surfactants; method to treat rosacea; and its use for the treatment of rosacea.
ES2593261B1 (en) PRODUCT IN CREAM OF TOPICAL USE FOR THE TREATMENT OF SKIN DISEASES AND PROCEDURE OF OBTAINING
MX2016007973A (en) Topical composition comprising natural ingredients for bruising or hematoma healing on skin and use thereof.
BRPI1002067A8 (en) LEISHMANICIDAL FORMULATION AND ITS USE
ES2536661B1 (en) Protein composition
ES2562085B1 (en) Cream for the treatment of skins with flaking states and manufacturing procedure of said cream
AR116927A1 (en) COMPOSITION FOR HAIR TREATMENT
ES2554204B1 (en) Crepe product for people and animals and elaboration process
Nersisyan et al. A based on natural ingredients technology for production of disinfectant and Anaesthetic toothpastes
CL2017002601A1 (en) Compositions for long-las¬ting moisturizing cosmetic formulation comprising ucuuba butter with high concentration of myristic acid, as well as the use of said formulation for the preparation of a highly moisturizing cosmetic product and kit
ES2596722B1 (en) MAGISTRAL FORMULA AND OBTAINING PROCEDURE
RU2022104737A (en) COMPOSITIONS FOR TREATMENT OF ATOPIC DERMATITIS
Priprem et al. SKIN PERMEATION, SKIN TOXICITY AND ANTI-INFLAMMATION OF HYDROGLYCOLIC EXTRACT FROM MYROBALAN FRUITS
ES2591056B1 (en) REGENERATING COSMETIC COMPOSITION
WO2014137304A2 (en) A skin cream

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2551281

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160914

FD2A Announcement of lapse in spain

Effective date: 20210915